NCT02899078View on ClinicalTrials.gov

Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

31

Participants

Timeline

Start Date

November 15, 2016

Primary Completion Date

August 5, 2020

Study Completion Date

February 24, 2021

Conditions

Metastatic Renal Cell CancerStage IV Renal Cell Cancer

Interventions

DRUG

Ibrutinib

Given PO

DRUG

Nivolumab

Given IV

Trial Locations (1)

95817

University of California Davis Comprehensive Cancer Center, Sacramento

Sponsors

Collaborators (1)

Pharmacyclics LLC.

All Listed Sponsors

collaborator

Pharmacyclics LLC.

INDUSTRY

lead

University of California, Davis

OTHER